EMA Application withdrawn: Vivjoa (oteseconazole) — Gedeon Richter Plc.

View source ↗

Summary

The EMA has withdrawn the application for Vivjoa (oteseconazole) by Gedeon Richter Plc. for candidiasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidiasis

Drugs mentioned

• VIVJOA (oteseconazole)

Snippet

Status: Application withdrawn. Therapeutic area: Candidiasis. MAH: Gedeon Richter Plc.